Kim Gallo Esthetics

DECEMBER 23, 2022

A microcurrent facial is a treatment that uses low-level electrical currents to stimulate the muscles and the skin. Microcurrent facials are one of my favorite treatments to perform because they offer so many benefits for the skin! At Kim Gallo Esthetics, your comfort and safety is our top priority.

Facials 195

Facials Esthetics Skin Types Collagen 195

The Dermatology Digest

MARCH 8, 2025

The Phase 3 TRuE-PN clinical trial program comprises TRuE-PN1 and TRuE-PN2 studies, which evaluate the safety and efficacy of twice-daily ruxolitinib cream 1.5% vs. vehicle control achieved an Investigator’s Global Assessment for Stage of Chronic Prurigo Treatment Success (IGA-CPG-S-TS) at Week 12 (15.8% respectively).

Safety 36

Safety Clinic Therapy Dermatology 36

The Dermatology Digest

MARCH 5, 2025

first pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) trial of Xyngari, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. The XYNGARI Phase 3 STAR-1 clinical study will evaluate the efficacy, safety, and tolerability of Xyngari in patients with moderate-to-severe facial acne.

Treatments 36

Treatments Rosacea Pores Office 36

The Dermatology Digest

MARCH 10, 2025

Th e Phase 3b, randomized, double-blind, placebo-controlled clinical trial included 99 patients with moderate-to-severe plaque psoriasis. ” The safety profile was consistent with the known safety profile of tildrakizumab, and no serious adverse events related to ILUMYA treatment occurred in this clinical trial,the study showed. .

Pharmaceutical 36

Pharmaceutical Safety Clinic Injections 36

Alison Bladh

JANUARY 16, 2025

Clinical studies indicate that saw palmetto can be an effective option for managing urinary symptoms during perimenopause and menopause, improving quality of life for many women. A randomised, double-blind, placebo-controlled study of the efficacy of a saw palmetto oral supplement in the treatment of androgenetic alopecia. 20210254.

Extractions 98

Extractions Management Consultations Consultation 98

The Dermatology Digest

FEBRUARY 25, 2025

This announcement follows the successful completion of a Phase I clinical trial involving 40 healthy volunteers, where ruxoprubart demonstrated promising results and a clean safety profile, with no serious adverse events reported.

Safety 36

Safety Therapy Clinic Dermatology 36

New Age Spa Institute

DECEMBER 18, 2024

In this blog, well build upon our discussion of licensure versus certification and explore the different classifications of certifications in esthetics and cosmetology, including Clinical Aesthetics and Master Clinical Aesthetics. Clinical Aesthetics Certification Who is this for? What Are Certifications? Want more info?

Medical 52

Medical Esthetics Legal Continuing Education 52

The Dermatology Digest

APRIL 7, 2024

A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). Nonsteroidal treatment options for AD have rapidly expanded in recent years with the development of phosphodiesterase-4 inhibitors, biologics, and Janus kinase (JAK) inhibitors.

Treatments 77

Treatments Dermatitis Therapy Medical 77

The Dermatology Digest

JANUARY 8, 2025

topical ET-02 may be more effective than existing treatments for androgenic alopecia, according to results of a first-in-man clinical trial. In a double-blind, placebo-controlled, dose-ranging clinical study of 24 subjects at three U.S. A final assessment of the subjects was made one week after the treatments ended.

Safety 36

Safety Clinic Pharmaceutical Treatments 36

Lipgloss and Aftershave

NOVEMBER 1, 2024

Jenni Nagle, L+A CO-Founder had a CO2 laser treatment and kept an eight day diary of her recovery process! Whether caused by sun exposure, hormonal fluctuations, post-inflammatory responses, or genetic factors, pigmentation can present unique challenges in clinical practice. Core Treatment Modalities for Skin Pigmentation 1.

Chemical Peels 52

Chemical Peels Hyperpigmentation Vitamin C Microneedling 52

Dermatology Times

AUGUST 23, 2023

While botulinum toxin has emerged as a treatment course for rosacea in recent years, researchers are calling for more comprehensive and detailed long-term research to assess its effectiveness.

Rosacea 69

Rosacea Safety Clinic Treatments 69

Lipgloss and Aftershave

FEBRUARY 21, 2025

This article will explore the key developments in the use of dermal fillers, including the trend of dissolving fillers, an emphasis on skin quality, the rise of combination treatments, and my personal experiences with innovative treatment protocols in my clinic.

Facials 52

Facials Hydration Injections Innovations 52

AAAMS

DECEMBER 19, 2024

Heres why it appeals to so many medical professionals: High Demand: Patients are increasingly seeking non-invasive cosmetic treatments, creating a steady demand for trained practitioners. Understanding patient safety protocols and treatment planning. Aesthetic medicine is one of the fastest-growing fields in healthcare.

Social Media 52

Social Media Work-Life Balance Training Microneedling 52

The Dermatology Digest

MARCH 9, 2025

The safety and efficacy of dupilumab in BP are currently under clinical investigation and have not been evaluated by any regulatory authority. During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained.

Sustainability 36

Sustainability Hospital Clinic Dermatology 36

The Dermatology Digest

MARCH 3, 2025

Vyjuvek (beremagene geperpavec-svdt, or B-VEC) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. a clinic) or at home. It is amazing how simple and non-invasive its use is, even in infants.

Therapy 36

Therapy Clinic Hospital Dermatology 36

The Dermatology Digest

NOVEMBER 30, 2024

Several new therapies are coming down the pike for the treatment of lichen planus, a chronic inflammatory condition that affects an estimated 1% to 2% of the global population, according to a new report from Research and Markets. Incyte is investigating the efficacy and safety of ruxolitinib cream in cutaneous lichen planus.

Pharmaceutical 36

Pharmaceutical Safety Marketing Therapy 36

Atelier Esthetique Institute of Esthetics

DECEMBER 5, 2023

Accrediting committees ensure that the quality and safety of your school is approved and noted by outside bodies. The Benefits of a Well-Rounded Curriculum If you’re going to esthetician school, you’ll want to know everything you can about the field, from skincare knowledge to the differences between treatments.

Esthetician 148

Esthetician Esthetics Education Training 148

Dermatology Times

JANUARY 27, 2025

A panelist discusses how laser treatments demonstrate a strong safety profile and proven efficacy for patients with acne, with clinical studies showing significant reduction in both inflammatory and noninflammatory lesions.

Safety 36

Safety Treatments Clinic 36

The Dermatology Digest

MARCH 10, 2025

The IGNITE study was a 24-week, randomized, placebo-controlled, double-blind study to assess the efficacy, safety and tolerability of rocatinlimab monotherapy every four weeks in 769 adults with moderate to severe AD, including patients previously treated with a biologic or systemic Janus kinase (JAK) inhibitor medication.

Dermatitis 36

Dermatitis Safety Office Eczema 36

Southeastern Esthetics Institute

AUGUST 23, 2016

Estheticians must obtain written permission and treatment plans through the physician overseeing the practice, with monitoring by the physician of all notations within patient charts, products and modalities used, and any other thought process made throughout the duration of treatment.

Esthetician 195

Esthetician Esthetics Document Office 195

The Dermatology Digest

FEBRUARY 18, 2025

The UK Medicines and Healthcare products Regulatory Agency and Swissmedic have granted the marketing authorization of nemolizumab for the treatment of both AD and PN in the UK and Switzerland, respectively. Food and Drug Administration for the treatment of AD and PN.

Dermatitis 36

Dermatitis Hospital Marketing Clinic 36

The Dermatology Digest

DECEMBER 3, 2024

The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization in Great Britain for delgocitinib cream (Anzupgo, Leo Pharma) for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate.

Marketing 36

Marketing Eczema Safety Management 36

US Dermatologt Partners

JANUARY 13, 2025

Professional acne extractions are clinical procedures where blackheads, whiteheads, and other types of blemishes are removed, during a dermatologic appointment. Dr. Desai says, Professional extractions are key to effective acne treatment, especially for patients with clogged pores that dont respond to topical treatments.

Extractions 41

Extractions Scarring Pores Chemical Peels 41

The Dermatology Digest

JANUARY 22, 2025

for review for the topical treatment of scalp and body psoriasis in patients aged 12 and up. Safety and Tolerability:Roflumilast foam was well tolerated across studies, with treatment-emergent adverse events (TEAEs) predominantly mild to moderate in severity. for the treatment of seborrheic dermatitis in patients 9 and older.

Dermatitis 36

Dermatitis Safety Treatments Clinic 36

The Dermatology Digest

DECEMBER 9, 2024

This FDA clearance was supported by AiVivas submission of safety data on non-facial skin tolerability and efficacy, and systemic exposure from 67 subjects treated with AIV001 in basal cell carcinoma and in scar management. To date, AiViva has completed three clinical studies using intradermal injection of AIV001.

Injections 36

Injections Facials Scarring Sensitive Skin 36

West Lake Dermatology

MARCH 10, 2025

Among treatment options, Mohs surgery uniformly produces the highest success rate and has the lower risk of tumor recurrence. Preparing for Surgery Arrival at the Clinic Patients typically arrive at the clinic early in the morning, as Mohs surgery often takes several hours depending on how many stages are required.

Surgery 36

Surgery Scarring Clinic Injections 36

Lipgloss and Aftershave

OCTOBER 30, 2024

Devices like Dio-Ice and Luxelight offer multiple wavelengths, and modalities in one platform, allowing for effective treatments on various skin types and hair densities. This versatility makes our devices suitable for a wide range of skin tones, from lighter to darker Fitzpatrick types, while maintaining comfort and safety.

Hair Removal 52

Hair Removal Skin Types Technology Safety 52

The Dermatology Digest

JANUARY 22, 2025

are partnering for a clinical trial collaboration agreement to evaluate the topical application of Xyngari (formerly known as DMT310), Dermatas topical Spongilla powder, with daxibotulinumtoxinA-lanm (Daxxify), Revances botulinum toxin type A. Dermata Therapeutics, Inc. and Revance Therapeutics, Inc.

Injections 36

Injections Office Partnerships Clinic 36

The Dermatology Digest

MARCH 18, 2024

Food and Drug Administration (FDA) has accepted Journey Medical’s New Drug Application (NDA) for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of November 4, 2024. “We

Rosacea 74

Rosacea Medical Office Clinic 74

The Dermatology Digest

APRIL 12, 2024

Recent cases where possibly counterfeit neurotoxins in Illinois and Tennessee led to a cluster of illnesses resembling Botulism highlight the need to strengthen patient safety through increased oversight of medical care in all settings, according to the American Society for Dermatologic Surgery Association (ASDSA).

Safety 69

Safety Surgery Medical Training 69

The Dermatology Digest

NOVEMBER 18, 2024

Safety data was found to be consistent with the Phase 2 FRONTIER 1 and 2 studies. of participants experiencing a treatment emergent adverse event (TEAE) at week 16. Further increases in response rates continued to be observed at week 24, with 74.1% of patients treated with icotrokinra achieving IGA scores of 0/1, and 64.9%

Safety 36

Safety Medical Innovations Dermatology 36

The Dermatology Digest

FEBRUARY 11, 2025

is restructuring to focus on the advancement of its bempikibart clinical development program for the treatment of patients with alopecia areata (AA). “We have conviction that bempikibart is differentiated from existing AA therapies and has the potential to transform the treatment paradigm for this disease. Q32 Bio Inc.

Clinic 36

Clinic Therapy Office Tools 36

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). The FDA has granted nemolizumab Priority Review for prurigo nodularis.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

JUNE 5, 2024

Top-line data from the 24-week vehicle-controlled treatment period are expected in mid-2025. The randomized, double-blind, vehicle-controlled trial will evaluate the safety and efficacy of once-daily VYN201 topical gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks.

Safety 73

Safety Office Facials Therapy 73

Dermatology Times

JANUARY 2, 2025

The panelist discusses how safety data from clinical trials and real-world evidence should guide physicians in prescribing ruxolitinib cream, including patient monitoring protocols and managing potential adverse effects in atopic dermatitis treatment.

Safety 36

Safety Dermatitis Management Clinic 36

The Dermatology Digest

DECEMBER 13, 2024

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.

Dermatitis 69

Dermatitis Safety Eczema Dermatology 69

Dermatology Times

OCTOBER 3, 2024

Brad Glick, DO, MPH, discusses how to effectively introduce photodynamic therapy (PDT) into a dermatology clinic by outlining necessary equipment and setup, providing guidance on essential patient discussions for treatment introduction, and sharing strategies to ensure treatment efficacy while prioritizing patient safety and satisfaction.

Clinic 36

Clinic Therapy Safety Dermatology 36